These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 20973926)
1. Erythropoiesis-stimulating agents and heart failure. Lipšic E; van der Meer P; van Veldhuisen DJ Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926 [TBL] [Abstract][Full Text] [Related]
2. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents. Lawler PR; Filion KB; Eisenberg MJ J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844 [TBL] [Abstract][Full Text] [Related]
3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
4. Future directions in management of anemia in heart failure. Agarwal AK; Katz SD Heart Fail Clin; 2010 Jul; 6(3):385-95. PubMed ID: 20630412 [TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment of anemia in heart failure patients]. Santilli G; Tarantini L; Baio P; Senni M G Ital Cardiol (Rome); 2011 May; 12(5):319-26. PubMed ID: 21593950 [TBL] [Abstract][Full Text] [Related]
10. [Erythropoesis-stimulating agents: past, present and future]. Kes P; Basić-Jukić N Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351 [TBL] [Abstract][Full Text] [Related]
11. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure. Doss S; Schiller B Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916 [TBL] [Abstract][Full Text] [Related]
12. [Role of renal anemia in progression of chronic kidney disease]. Racki S; Maleta I Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353 [TBL] [Abstract][Full Text] [Related]
13. [Anaemia in chronic heart failure]. Hradec J Vnitr Lek; 2010 Aug; 56(8):854-9. PubMed ID: 20845618 [TBL] [Abstract][Full Text] [Related]
14. The interaction between heart failure and other heart diseases, renal failure, and anemia. Silverberg DS; Wexler D; Iaina A; Schwartz D Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468 [TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated. Nowrousian MR; Dunst J; Vaupel P Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508 [TBL] [Abstract][Full Text] [Related]
16. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. van der Meer P; Groenveld HF; Januzzi JL; van Veldhuisen DJ Heart; 2009 Aug; 95(16):1309-14. PubMed ID: 19168472 [TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. Schmid H; Schiffl H; Lederer SR Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032 [TBL] [Abstract][Full Text] [Related]
18. Erythropoietin in cancer patients. Glaspy JA Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468 [TBL] [Abstract][Full Text] [Related]